Bind Therapeutics and Roche collaborate

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

Roche (RHHBY) signs a research agreement with Bind Therapeutics (BIND) to discover novel nanomedicines in therapeutic areas outside of oncology using Bind's Accurins technology. The focus for the research is combining Accurins with Roche's proprietary therapeutic payloads and targeting ligands.

Financial terms are not disclosed.